AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — FY2012 Earnings Presentation

12 slides from AMAG Pharmaceuticals's earnings presentation, Mar 15, 2013

  1. Slide 1: AMAG Pharmaceuticals 2012 Financial Results

    AMAG PHARMACEUTICALS 2012 Financial Results

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to: (i) o

  3. Slide 3: AMAG: 2012 Highlights

    AMAG: 2012 HIGHLIGHTS Continued growth of Feraheme U.S. CKD business Drove 17% Feraheme volume growth in the US compared to 2011 Exited year with 14% market share in grams Improved net revenue per gram for Feraheme Significant progress in Feraheme expansion efforts Completed phase III program for br

  4. Slide 4: Feraheme US CKD Business

    FERAHEME US CKD BUSINESS

  5. Slide 5: 2012 – Strong Growth in Feraheme Provider Demand

    2012 – STRONG GROWTH IN FERAHEME PROVIDER DEMAND 5 Source: IMS Health Data. 17% Grams 2012 Results 17% increase in Feraheme provider demand; 115 evolution index 4th Quarter Share 14% of non-dialysis IV iron market 26% of heme/onc segment 9% of hospital segment 37% of nephrology segment

  6. Slide 6: Strong Feraheme Growth in Heme/Onc Segment

    STRONG FERAHEME GROWTH IN HEME/ONC SEGMENT 6 Source: IMS Health Data. 63% 19% 12-Month Performance Feraheme up 19% Market up 6% 4Q12 vs. 4Q11 Feraheme up 11% Market up 2% Segment evolution index 109

  7. Slide 7: Strong Feraheme Growth in Hospital Segment

    STRONG FERAHEME GROWTH IN HOSPITAL SEGMENT 7 Source: IMS Health Data. 47% 33% 12-Month Performance Feraheme up 33% Market up 1% 4Q12 vs. 4Q11 Feraheme up 26% Market up 1% Segment evolution index 125

  8. Slide 8: Feraheme Performing Well, With a Bright Future

    FERAHEME PERFORMING WELL, WITH A BRIGHT FUTURE Continue to outpace market growth Gain access to untapped target heme/onc accounts Gain more hospital accounts Expand the IV iron market Present key data and medical meetings Continue to build awareness of Feraheme and of iron deficiency anemia 8

  9. Slide 9: Financial Overview

    | FINANCIAL OVERVIEW

  10. Slide 10: Year-End Financial Highlights

    YEAR-END FINANCIAL HIGHLIGHTS Balance Sheet $227 million in cash and investments as of December 31, 2012 ($ in millions, except per share ) 2012 2011 Change Total Revenues $85.4 $61.3 39% Net Feraheme US Product Revenues $58.3 $52.1 12% Cost of Product Sales $14.2 $10.5 35% R&D Expenses $33.3 $58.1

  11. Slide 11: 2013 Financial Outlook

    2013 FINANCIAL OUTLOOK 11 Expenses ($ in millions) Total Revenues of $73 - $77 million $63 – $67 million in Feraheme net U.S. product revenue Operating expenses of $78– $82 million (excluding COGS) R&D expenses decline New Investments for IDA launch COGS: 14%-18% of product sales End 2013 with $206

  12. Slide 12: AMAG Pharmaceuticals: Well positioned for growth in 2013 and beyond

    AMAG PHARMACEUTICALS Well positioned for growth in 2013 and beyond

Amag Pharmaceuticals — FY2012 Earnings Presentation on 6ix